Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central
nervous system afflicting nearly three million individuals worldwide. Neuroimmune …

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Barriers between circulation and the central nervous system (CNS) play a key role in the
development and modulation of CNS immune responses. Structural variations in the …

Background The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is
unknown. Methods In an integrated study with separate induction and maintenance trials …

Background Multiple sclerosis is an acquired demyelinating disease of the central nervous
system. It is the second most common cause of disability in adults in United States after head …

Background & Aims There is an increasing need for new treatments for patients with Crohn's
disease (CD) in whom previous therapy with tumor necrosis factor (TNF) antagonists has …

Background Progressive multifocal leukoencephalopathy (PML) is associated with
natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis …

Objective: To establish criteria for the diagnosis of progressive multifocal
leukoencephalopathy (PML). Methods: We reviewed available literature to identify various …

Approaches for the effective management of acute stroke are sparse, and many measures
for brain protection fail. However, our ability to modulate the immune system and modify the …

Six biologic agents are currently approved for the treatment of IBD: four anti-TNF agents
(infliximab, adalimumab, golimumab and certolizumab pegol) and two anti-integrin agents …